[Colchicine treatment of renal amylosis in familial paroxysmal polyserositis (author's transl)].
Mortality in familial paroxysmal polyserositis results mainly from renal amylosis, the outcome, until recently, being always fatal. Continuous colchicine administration prevents acute relapses, but certain recent observations have demonstrated that this treatment may be able to prevent the onset of amyloid disease. It could even provoke its regression, at least if administration is during the early stages before the development of renal insufficiency. The mechanism of this preventive action against amyloid disease occurrence is discussed as a function of current knowledge of amyloidogenesis.
D000293:Adolescent; D000328:Adult; D000368:Aged; D000686:Amyloidosis / Q000188:drug therapy* / Q000517:prevention & control; D003078:Colchicine / Q000009:adverse effects / Q000494:pharmacology / Q000627:therapeutic use*; D004705:Endocytosis / Q000187:drug effects; D010505:Familial Mediterranean Fever / Q000150:complications*; D006801:Humans; D007674:Kidney Diseases / Q000188:drug therapy* / Q000517:prevention & control; D000685:Serum Amyloid A Protein / Q000096:biosynthesis
D000685:Serum Amyloid A Protein; D003078:Colchicine
Colchicine et amylose rénale de la maladie périodique.